{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Related Serious Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"38"}]}],"title":"Related Non-Serious Adverse Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Toxicity was assessed as the number of related non-serious adverse events and related serious adverse events (SAEs) reported by dose level (Cohort A or Cohort B) for the 12-cycle treatment period plus follow-up.","groups":[{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 100 mg once daily.","id":"OG000","title":"Enasidenib Mesylat 100mg"},{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 200 mg once daily.","id":"OG001","title":"Enasidenib Mesylat 200mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months","title":"Related Adverse Events","type":"SECONDARY","unitOfMeasure":"Adverse Events"}